Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

F. Griesinger, G. Curigliano, M. Thomas, V. Subbiah, C. S. Baik, D. S.W. Tan, D. H. Lee, D. Misch, E. Garralda, D. W. Kim, A. J. van der Wekken, J. F. Gainor, L. Paz-Ares, S. V. Liu, G. P. Kalemkerian, Y. Houvras, D. W. Bowles, A. S. Mansfield, J. J. Lin, V. SmoljanovicA. Rahman, S. Kong, A. Zalutskaya, M. Louie-Gao, A. L. Boral, J. Mazières

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial'. Together they form a unique fingerprint.

Medicine & Life Sciences